Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9,421 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Switching from natalizumab to antiCD20 monoclonal antibodies: Short transition interval is associated with improved outcome.
Bsteh G, Hoepner R, Gernert JA, Berek K, Gradl C, Kliushnikova D, Damulina A, Traxler G, Föttinger F, Habernig S, Krajnc N, Betancourt AXL, Ponleitner M, Zrzavy T, Deisenhammer F, Di Pauli F, Havla J, Khalil M, Kümpfel T, Wipfler P, Chan A, Berger T, Hammer H, Hegen H. Bsteh G, et al. Among authors: chan a. Eur J Neurol. 2025 Jan;32(1):e16587. doi: 10.1111/ene.16587. Eur J Neurol. 2025. PMID: 39686558 Free PMC article.
Association of Disease-Modifying Treatment With Outcome in Patients With Relapsing Multiple Sclerosis and Isolated MRI Activity.
Bsteh G, Aicher ML, Walde JF, Krajnc N, Haider L, Traxler G, Gradl C, Salmen A, Riedl K, Poskaite P, Leyendecker P, Altmann P, Auer M, Berek K, Di Pauli F, Kornek B, Leutmezer F, Rommer PS, Zulehner G, Zrzavy T, Deisenhammer F, Chan A, Berger T, Hoepner R, Hammer H, Hegen H. Bsteh G, et al. Among authors: chan a. Neurology. 2024 Sep 24;103(6):e209752. doi: 10.1212/WNL.0000000000209752. Epub 2024 Aug 28. Neurology. 2024. PMID: 39197111
L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients.
Schwab N, Schneider-Hohendorf T, Posevitz V, Breuer J, Göbel K, Windhagen S, Brochet B, Vermersch P, Lebrun-Frenay C, Posevitz-Fejfár A, Capra R, Imberti L, Straeten V, Haas J, Wildemann B, Havla J, Kümpfel T, Meinl I, Niessen K, Goelz S, Kleinschnitz C, Warnke C, Buck D, Gold R, Kieseier BC, Meuth SG, Foley J, Chan A, Brassat D, Wiendl H. Schwab N, et al. Among authors: chan a. Neurology. 2013 Sep 3;81(10):865-71. doi: 10.1212/WNL.0b013e3182a351fb. Epub 2013 Aug 7. Neurology. 2013. PMID: 23925765
Disability progression is a question of definition-A methodological reappraisal by example of primary progressive multiple sclerosis.
Bsteh G, Marti S, Krajnc N, Traxler G, Salmen A, Hammer H, Leutmezer F, Rommer P, Di Pauli F, Chan A, Berger T, Hegen H, Hoepner R. Bsteh G, et al. Among authors: chan a. Mult Scler Relat Disord. 2024 Dec 6;93:106215. doi: 10.1016/j.msard.2024.106215. Online ahead of print. Mult Scler Relat Disord. 2024. PMID: 39662164 Free article.
[Progress in the treatment of multiple sclerosis].
Chan A, Kamber N, Hoepner R, Salmen A. Chan A, et al. Ther Umsch. 2018;75(7):405-409. doi: 10.1024/0040-5930/a001016. Ther Umsch. 2018. PMID: 30935353 Review. German.
9,421 results